Skip to main content
Premium Trial:

Request an Annual Quote

DxS Doubles R&D Staff

NEW YORK (GenomeWeb News) – British molecular diagnostics firm DxS today said that it has doubled its research and development staff from four to eight during the final quarter of this year.
 
The Manchester-based firm said that it also plans to recruit five more product development scientists within the next month. It said that the increase in staff was due to a “marked rise in demand” for its cancer diagnostic kits.
 
DxS recently launched a PI3K Mutation Test Kit based on its real-time PCR technology, called Scorpions, and its ARMS SNP detection technology. It sells other kits for detection of cancer-related mutations under the TheraScreen brand name.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.